The development of next generation sequencing (NGS) has led to marked advancement of our understanding of genetic events mediating the initiation and progression of thyroid cancers. The NGS studies have confirmed the previously reported high frequency of mutually-exclusive oncogenic alterations affecting BRAF and RAS proto-oncogenes in all stages of thyroid cancer. Initially identified by traditional sequencing approaches, the NGS studies also confirmed the acquisition of alterations that inactivate tumor protein p53 (TP53) and activate phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) in advanced thyroid cancers. Novel alterations, such as those in telomerase reverse transcriptase (TERT) promoter and mating-type switching/sucrose non-fermenting (SWI/SNF) complex, are also likely to promote progression of the BRAF^V600E-driven thyroid cancers. A number of genetically engineered mouse models (GEMM) of BRAF^V600E-driven thyroid cancer have been developed to investigate thyroid tumorigenesis mediated by oncogenic BRAF and to explore the role of genetic alterations identified in the genomic analyses of advanced thyroid cancer to promote tumor progression. This review will discuss the various GEMMs that have been developed to investigate oncogenic BRAF^V600E-driven thyroid cancers.

Citations

Citations to this article as recorded by  

• Strategies to investigate migration and metastases in thyroid cancer
  Daniel M. Chopyk, Priya H. Dedhia
  Current Opinion in Endocrine and Metabolic Research.2024; 34: 100502.     CrossRef
• Comparative efficiency of differential diagnostic methods for the identification of BRAF V600E gene mutation in papillary thyroid cancer (Review)
  Qian Liu, Xue Jiang, Wenling Tu, Lina Liu, Ying Huang, Yuxiao Xia, Xuliang Xia, Yuhong Shi
  Experimental and Therapeutic Medicine.2024;[Epub]     CrossRef
• Mouse Models to Examine Differentiated Thyroid Cancer Pathogenesis: Recent Updates
  Hye Choi, Kwangsoon Kim
  International Journal of Molecular Sciences.2023; 24(13): 11138.     CrossRef
• Mechanistic Insights of Thyroid Cancer Progression
  Luis Javier Leandro-García, Iñigo Landa
  Endocrinology.2023;[Epub]     CrossRef
• Anaplastic thyroid cancer: Pathogenesis, prognostic factors and genetic landscape (Review)
  Abdul-Mohsen Alhejaily, Omar Alhuzim, Yazeed Alwelaie
  Molecular and Clinical Oncology.2023;[Epub]     CrossRef
• Tissue architecture delineates field cancerization in BRAFV600E-induced tumor development
  Elin Schoultz, Ellen Johansson, Carmen Moccia, Iva Jakubikova, Naveen Ravi, Shawn Liang, Therese Carlsson, Mikael Montelius, Konrad Patyra, Jukka Kero, Kajsa Paulsson, Henrik Fagman, Martin O. Bergo, Mikael Nilsson
  Disease Models & Mechanisms.2022;[Epub]     CrossRef
• BRAFV600E Expression in Thyrocytes Causes Recruitment of Immunosuppressive STABILIN-1 Macrophages
  Catherine Spourquet, Ophélie Delcorte, Pascale Lemoine, Nicolas Dauguet, Axelle Loriot, Younes Achouri, Maija Hollmén, Sirpa Jalkanen, François Huaux, Sophie Lucas, Pierre Van Meerkeeck, Jeffrey A. Knauf, James A. Fagin, Chantal Dessy, Michel Mourad, Patr
  Cancers.2022; 14(19): 4687.     CrossRef
• Positive BRAFV600E mutation of primary tumor influences radioiodine avidity but not prognosis of papillary thyroid cancer with lung metastases
  Shuhui Huang, Mengfang Qi, Tian Tian, Hongyuan Dai, Yuan Tang, Rui Huang
  Frontiers in Endocrinology.2022;[Epub]     CrossRef
• Preclinical Models of Follicular Cell-Derived Thyroid Cancer: An Overview from Cancer Cell Lines to Mouse Models
  Min Ji Jeon, Bryan R. Haugen
  Endocrinology and Metabolism.2022; 37(6): 830.     CrossRef
• An Animal Model Further Uncovers the Role of Mutant Braf during Papillary Thyroid Cancer Development
  Bernd Koelsch, Sarah Theurer, Magdalena Staniszewska, Jacqueline Heupel, Amelie Koch, Svenja Mergener, Franziska Walk, Christine Fischer, Andrea Kutritz, Kurt W. Schmid, Andrea Kindler-Röhrborn
  The American Journal of Pathology.2020; 190(3): 702.     CrossRef
• Intratumoral Genetic Heterogeneity in Papillary Thyroid Cancer: Occurrence and Clinical Significance
  Laura Fugazzola, Marina Muzza, Gabriele Pogliaghi, Mario Vitale
  Cancers.2020; 12(2): 383.     CrossRef
• The Aryl Hydrocarbon Receptor Is Expressed in Thyroid Carcinoma and Appears to Mediate Epithelial-Mesenchymal-Transition
  Sonia Moretti, Nicole Nucci, Elisa Menicali, Silvia Morelli, Vittorio Bini, Renato Colella, Martina Mandarano, Angelo Sidoni, Efisio Puxeddu
  Cancers.2020; 12(1): 145.     CrossRef